Take Solutions, an international business technology firm, today said it has entered into an agreement with South Korea-based IL-Yang Pharma Company Ltd for providing investigational new drug (IND) submission services to the company.
The purpose of the IND submission is to gain Food and Drug Administration (FDA) non-objection to study the investigational agent in humans, Take Solutions said in a filing to the Bombay Stock Exchange.
"Our reworked strategy toward focusing on the Asia Pacific region has received a major boost with IL-Yang Pharma," Take Solutions Vice President — sales, Life Sciences APAC, L Ramesh said.
The IND submission must include, sufficient preclinical data, details of chemistry and description of mechanism of action of the agent, the filing added.
Shares of Take Solutions were trading at Rs 38.30, up 8.50 per cent on the BSE.
